Scarica l'app Stockscreener
504.73
0.40%
-2.01
Dopo l'orario di chiusura:
504.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy - PharmaLive
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
Vertex Pharmaceuticals- Still Too Much Emphasis On CF SupremacyI Foresee A Downgrade - Seeking Alpha
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - The Motley Fool
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance
Vertex Pharmaceuticals stock last trades at USD 526.66 on September 28, 2026 - AD HOC NEWS
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating - Moomoo
Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript - Fortune
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. - Barron's
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals stock tracks kidney pipeline progress - AD HOC NEWS
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - fortune.com
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV) - The Globe and Mail
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues - Yahoo Finance
Vertex Pharma options analysis: heavy put activity signals near-term caution - Investing.com
Allstate, Autozone, Vertex Pharmaceuticals - TradingView
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex reports positive Phase IIb data as it completes enrollment in pivotal AMKD trial - The Pharma Letter
Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - Yahoo Finance
Jefferies raises Vertex stock price target on kidney drug data By Investing.com - Investing.com Canada
Vertex reports results from Phase IIb AMPLIFIED trial for AMKD - Clinical Trials Arena
TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating - Yahoo Finance
What could reshape the outlook for Vertex Pharmaceuticals (NASDAQ:VRTX) now? - Kalkine Media
Vertex Pharma stock gains 3 percent ahead of the open - AD HOC NEWS
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex Kidney Pill Shows Broader Promise, Lifting Rival Maze 25% - finance.biggo.com
Vertex Pharmaceuticals Stock Gains On Kidney Drug DataVertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder - Yahoo Finance
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
BMO reiterates Vertex stock rating on positive trial data By Investing.com - Investing.com Canada
Vertex Pharmaceuticals stock gains as inaxaplin data advance - AD HOC NEWS
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial - BioSpace
Vertex’s midstage data amplify kidney disease market opportunity - Fierce Biotech
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria - TradingView
Urine protein fell 42.7% in a kidney trial. Vertex finished enrolling its next study. - Stock Titan
Inside the Vertex Pharmaceuticals (VRTX) Story Reshaping Healthcare Stocks Sentiment - Kalkine Media
Vertex Pharma stock slips 1.55 percent pre-market before the open - ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Powerhouse with 11.97% Potential Upside - DirectorsTalk Interviews
Fierce Biotech Layoff Tracker 2026: Novo reveals 4k more employees were laid off; Sionna halves staff - Fierce Biotech
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? - The Motley Fool
2 Reasons to Like VRTX (and 1 Not So Much) - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Vertex Pharmaceuticals (VRTX), Why Is It Getting Fresh Attention Now? - Yahoo Finance
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX - Business Wire
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead - TradingView
0.57%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):